{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:06:07Z","timestamp":1789383967383,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda (China) International Trading Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40487-026-00456-5","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:47:00Z","timestamp":1784033220000},"page":"919-937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Comprehensive Mapping of Real-World Studies and Data Sources for Oncology in China: Insights into Landscape, Challenges, and Future Direction"],"prefix":"10.1007","volume":"14","author":[{"given":"Yaqi","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff Jianfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"456_CR1","doi-asserted-by":"publisher","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","volume":"25","author":"M Di Maio","year":"2020","unstructured":"Di Maio M, Perrone F, Conte P. Real\u2010world evidence in oncology: opportunities and limitations. Oncologist. 2020;25:e746\u201352. https:\/\/doi.org\/10.1634\/theoncologist.2019-0647.","journal-title":"Oncologist"},{"key":"456_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/JMDH.S160029","volume":"11","author":"VB Katkade","year":"2018","unstructured":"Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295\u2013304. https:\/\/doi.org\/10.2147\/JMDH.S160029.","journal-title":"J Multidiscip Healthc"},{"key":"456_CR3","doi-asserted-by":"publisher","unstructured":"Saesen R, Hemelrijck MV, Bogaerts J, Booth CM, Cornelissen JJ, Dekker A, et al. Defining the role of real-world data in cancer clinical research: the position of the European Organisation for Research and Treatment of Cancer. Eur J Cancer [Internet]. Elsevier; 2023 [cited 2023 Mar 29];0. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.013","DOI":"10.1016\/j.ejca.2023.03.013"},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.3390\/curroncol29030165","volume":"29","author":"WF Dai","year":"2022","unstructured":"Dai WF, de Oliveira C, Blommaert S, Pataky RE, Tran D, Aurangzeb Z, et al. Mapping Canadian data assets to generate real-world evidence: lessons learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration\u2019s RWE Data Working Group. Curr Oncol. 2022;29:2046\u201363. https:\/\/doi.org\/10.3390\/curroncol29030165.","journal-title":"Curr Oncol"},{"key":"456_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejca.2021.07.001","volume":"155","author":"JM Boyle","year":"2021","unstructured":"Boyle JM, Hegarty G, Frampton C, Harvey-Jones E, Dodkins J, Beyer K, et al. Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: a retrospective cohort study. Eur J Cancer. 2021;155:136\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2021.07.001.","journal-title":"Eur J Cancer"},{"key":"456_CR6","doi-asserted-by":"publisher","unstructured":"Kc S, Lin LW, Bayani DBS, Zemlyanska Y, Adler A, Ahn J, et al. What, where, and how to collect real-world data and generate real-world evidence to support drug reimbursement decision-making in Asia: a reflection into the past and a way forward. Int J Health Policy Manag [Internet]. Kerman University of Medical Sciences; 2023 [cited 2023 Mar 29]. https:\/\/doi.org\/10.34172\/ijhpm.2023.6858.","DOI":"10.34172\/ijhpm.2023.6858"},{"key":"456_CR7","first-page":"1","volume":"7","author":"Y Kong","year":"2021","unstructured":"Kong Y. The application of real-world study for liver diseases in China. Jpn J Gstro Hepato. 2021;7:1\u20137.","journal-title":"Jpn J Gstro Hepato"},{"key":"456_CR8","unstructured":"EMA. Global regulators call for international collaboration to integrate real-world evidence into regulatory decision-making [Internet]. European Medicines Agency. 2022 [cited 2023 Apr 3]. https:\/\/www.ema.europa.eu\/en\/news\/global-regulators-call-international-collaboration-integrate-real-world-evidence-regulatory-decision. Accessed 3 Apr 2023."},{"key":"456_CR9","doi-asserted-by":"publisher","first-page":"A587","DOI":"10.1016\/j.jval.2014.08.2006","volume":"17","author":"M Batrouni","year":"2014","unstructured":"Batrouni M, Comet D, Meunier JP. Real world studies, challenges, needs and trends from the industry. Value Health. 2014;17:A587\u20138. https:\/\/doi.org\/10.1016\/j.jval.2014.08.2006.","journal-title":"Value Health"},{"key":"456_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cpt.2461","volume":"111","author":"R Flynn","year":"2022","unstructured":"Flynn R, Plueschke K, Quinten C, Strassmann V, Duijnhoven RG, Gordillo-Mara\u00f1on M, et al. marketing authorization applications made to the European Medicines Agency in 2018\u20132019: what was the contribution of real-world evidence? Clin Pharmacol Ther. 2022;111:90\u20137. https:\/\/doi.org\/10.1002\/cpt.2461.","journal-title":"Clin Pharmacol Ther"},{"key":"456_CR11","doi-asserted-by":"publisher","first-page":"S389","DOI":"10.1016\/j.jval.2019.04.1903","volume":"22","author":"B Cai","year":"2019","unstructured":"Cai B, Xie Y, Gong Y, Luo W, Qu H, Liu J. RW4 development of real-world data and the use of RWD for evidence generation in China. Value Health. 2019;22:S389\u201390. https:\/\/doi.org\/10.1016\/j.jval.2019.04.1903.","journal-title":"Value Health"},{"key":"456_CR12","unstructured":"China: preferential policies related to drug application registration by using Real-World Evidence (RWE) in Hainan Medical Pilot | Remedy & Company Corporation [Internet]. [cited 2023 Apr 4]. https:\/\/www.remedy-company.com\/en\/column\/global_nl\/202103_1_china.html. Accessed 4 Apr 2023."},{"key":"456_CR13","unstructured":"NMPA issued the announcement on the guidelines for real-world evidence to support drug development and review (Interim) [Internet]. [cited 2023 Apr 4]. http:\/\/english.nmpa.gov.cn\/2020-01\/07\/c_456245.htm. Accessed 4 Apr 2023."},{"key":"456_CR14","unstructured":"Yu T. NMPA approves the first medical device through real-world data program [Internet]. China Med Device. 2020 [cited 2023 Apr 4]. https:\/\/chinameddevice.com\/real-world-data-nmpa\/. Accessed 4 Apr 2023."},{"key":"456_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"456_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231175441","author":"K Jung","year":"2023","unstructured":"Jung K, Choi S, Song H, Kwak K, Anh S, Jung JH, et al. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Ther Adv Med Oncol. 2023. https:\/\/doi.org\/10.1177\/17588359231175441.","journal-title":"Ther Adv Med Oncol."},{"key":"456_CR17","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S1470-2045(20)30073-5","volume":"21","author":"W Wei","year":"2020","unstructured":"Wei W, Zeng H, Zheng R, Zhang S, An L, Chen R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020;21:e342\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(20)30073-5.","journal-title":"Lancet Oncol"},{"key":"456_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","volume":"16","author":"CM Booth","year":"2019","unstructured":"Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. 2019;16:312\u201325. https:\/\/doi.org\/10.1038\/s41571-019-0167-7.","journal-title":"Nat Rev Clin Oncol"},{"key":"456_CR19","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/cncr.32697","volume":"126","author":"CM Phillips","year":"2020","unstructured":"Phillips CM, Parmar A, Guo H, Schwartz D, Isaranuwatchai W, Beca J, et al. Assessing the efficacy-effectiveness gap for cancer therapies: a comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics. Cancer. 2020;126:1717\u201326. https:\/\/doi.org\/10.1002\/cncr.32697.","journal-title":"Cancer"},{"key":"456_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3322\/caac.21714","volume":"72","author":"LT Penberthy","year":"2022","unstructured":"Penberthy LT, Rivera DR, Lund JL, Bruno MA, Meyer A-M. An overview of real-world data sources for oncology and considerations for research. CA Cancer J Clin. 2022;72:287\u2013300. https:\/\/doi.org\/10.3322\/caac.21714.","journal-title":"CA Cancer J Clin"},{"key":"456_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.vhri.2021.05.002","volume":"27","author":"J Xie","year":"2022","unstructured":"Xie J, Wu EQ, Wang S, Cheng T, Zhou Z, Zhong J, et al. Real-world data for healthcare research in China: call for actions. Value Health Reg Issues. 2022;27:72\u201381. https:\/\/doi.org\/10.1016\/j.vhri.2021.05.002.","journal-title":"Value Health Reg Issues"},{"key":"456_CR22","doi-asserted-by":"publisher","first-page":"j5262","DOI":"10.1136\/bmj.j5262","volume":"360","author":"X Sun","year":"2018","unstructured":"Sun X, Tan J, Tang L, Guo JJ, Li X. Real world evidence: experience and lessons from China. BMJ. 2018;360:j5262. https:\/\/doi.org\/10.1136\/bmj.j5262.","journal-title":"BMJ"},{"key":"456_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40264-017-0589-z","volume":"41","author":"Y Yang","year":"2018","unstructured":"Yang Y, Zhou X, Gao S, Lin H, Xie Y, Feng Y, et al. Evaluation of electronic healthcare databases for post-marketing drug safety surveillance and pharmacoepidemiology in China. Drug Saf. 2018;41:125\u201337. https:\/\/doi.org\/10.1007\/s40264-017-0589-z.","journal-title":"Drug Saf"},{"key":"456_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063139","volume":"12","author":"J Zhong","year":"2022","unstructured":"Zhong J, Zhang J, Fang H, Liu L, Xie J, Wu E. Advancing the development of real-world data for healthcare research in China: challenges and opportunities. BMJ Open. 2022;12:e063139. https:\/\/doi.org\/10.1136\/bmjopen-2022-063139.","journal-title":"BMJ Open"},{"key":"456_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006704","volume":"96","author":"J-K Chiang","year":"2017","unstructured":"Chiang J-K, Lin C-W, Wang C-L, Koo M, Kao Y-H. Cancer studies based on secondary data analysis of the Taiwan\u2019s National Health Insurance Research Database. Medicine (Baltimore). 2017;96:e6704. https:\/\/doi.org\/10.1097\/MD.0000000000006704.","journal-title":"Medicine (Baltimore)"},{"key":"456_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276992","volume":"17","author":"H Xia","year":"2022","unstructured":"Xia H, Qingchun L, Baptista EA. Spatial heterogeneity of internal migration in China: the role of economic, social and environmental characteristics. PLoS ONE. 2022;17:e0276992. https:\/\/doi.org\/10.1371\/journal.pone.0276992.","journal-title":"PLoS ONE"},{"key":"456_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/cac2.12025","volume":"40","author":"M Cao","year":"2020","unstructured":"Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun. 2020;40:205\u201310. https:\/\/doi.org\/10.1002\/cac2.12025.","journal-title":"Cancer Commun"},{"key":"456_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144809","volume":"10","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zhao L, Cui Z, Wang Y. Study on equity and efficiency of health resources and services based on key indicators in China. PLoS ONE. 2015;10:e0144809. https:\/\/doi.org\/10.1371\/journal.pone.0144809.","journal-title":"PLoS ONE"},{"key":"456_CR29","first-page":"212","volume":"26","author":"W Xiaodong","year":"2019","unstructured":"Xiaodong W, Xi L, Xinlin H, Li L. Database research part \u2160: colorectal cancer from reginal medical center and population characteristics. Chin J Basic Clin Gen Surg. 2019;26:212\u201320.","journal-title":"Chin J Basic Clin Gen Surg"},{"key":"456_CR30","first-page":"1209","volume":"28","author":"W Xiaodong","year":"2021","unstructured":"Xiaodong W, Li L. Database research part \u216a: follow-up of colorectal cancer. Chin J Basic Clin Gen Surg. 2021;28:1209\u201314.","journal-title":"Chin J Basic Clin Gen Surg"},{"key":"456_CR31","first-page":"1353","volume":"28","author":"W Xiaodong","year":"2021","unstructured":"Xiaodong W, Jiayi Z, Li L. Part \u216a of database building: tag and structure of follow-up of colorectal cancer. Chin J Basic Clin Gen Surg. 2021;28:1353\u20139.","journal-title":"Chin J Basic Clin Gen Surg"},{"key":"456_CR32","first-page":"335","volume":"26","author":"W Xiaodong","year":"2019","unstructured":"Xiaodong W, Li L. Part \u2160 of database building: tag and structure of personal data for Database from Colorectal Cancer in West China Hospital. Chin J Basic Clin Gen Surg. 2019;26:335\u201342.","journal-title":"Chin J Basic Clin Gen Surg"},{"key":"456_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13690-020-00436-9","volume":"78","author":"R Haneef","year":"2020","unstructured":"Haneef R, Delnord M, Vernay M, Bauchet E, Gaidelyte R, Van Oyen H, et al. Innovative use of data sources: a cross-sectional study of data linkage and artificial intelligence practices across European countries. Arch Public Health. 2020;78:55. https:\/\/doi.org\/10.1186\/s13690-020-00436-9.","journal-title":"Arch Public Health"},{"key":"456_CR34","doi-asserted-by":"publisher","unstructured":"Jia Y, Zhan S, Guo JJ, Cao X, Zhang YJ. RWD162 an overview of real-world data sources for real-world studies in oncology and rare diseases in China. Value Health [Internet]. Elsevier; 2023 [cited 2025 Sept 23];26:S392. https:\/\/doi.org\/10.1016\/j.jval.2023.03.2190.","DOI":"10.1016\/j.jval.2023.03.2190"},{"key":"456_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5237-1","volume":"19","author":"A Leng","year":"2019","unstructured":"Leng A, Jing J, Nicholas S, Wang J. Geographical disparities in treatment and health care costs for end-of-life cancer patients in China: a retrospective study. BMC Cancer. 2019;19:39. https:\/\/doi.org\/10.1186\/s12885-018-5237-1.","journal-title":"BMC Cancer"},{"key":"456_CR36","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.21037\/tlcr-21-388","volume":"10","author":"J-W Cui","year":"2021","unstructured":"Cui J-W, Zhou Q, Lu S, Cheng Y, Wang J, Bai R-L, et al. The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options. Transl Lung Cancer Res. 2021;10:3594\u2013607. https:\/\/doi.org\/10.21037\/tlcr-21-388.","journal-title":"Transl Lung Cancer Res"},{"key":"456_CR37","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler H-G, Goettsch W, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26:1033\u20139. https:\/\/doi.org\/10.1002\/pds.4297.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"456_CR38","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pds.4295","volume":"26","author":"SV Wang","year":"2017","unstructured":"Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, et al. Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0. Pharmacoepidemiol Drug Saf. 2017;26:1018\u201332. https:\/\/doi.org\/10.1002\/pds.4295.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00456-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00456-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00456-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:32:13Z","timestamp":1789381933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00456-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00456-5","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yaqi Jia, Yan-Jun Zhang, Ziheng Guo, and Xian Cao are employees of Takeda (China) International Trading Co. Yanbing Li, Siyan Zhan, and Jeff Jianfei Guo have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}